ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) has announced a significant advancement in its universal dengue vaccine initiative, marking a key step from AI-driven discovery to preclinical validation. Building on its earlier success in identifying a highly conserved dengue epitope using its LENSai™ platform powered by patented HYFT® technology, the company has now begun manufacturing the validated epitope for in vivo testing. The manufactured antigen will be used in proprietary immunization studies conducted at ImmunoPrecise’s Canadian facility using a rabbit model. These studies aim to assess whether the vaccine candidate can generate strong and protective monoclonal antibody (mAb) responses—critical for evaluating potential efficacy in humans. Dr. Jennifer Bath, CEO of ImmunoPrecise, emphasized the importance of this milestone: “This is the natural next step in our journey from AI discovery to real-world validation. We’ve demonstrated that HYFT technology can uncover unique, conserved, and immunologically relevant targets that traditional methods often miss. Now, we’re moving into live animal studies to answer the pivotal question: can this target provoke a powerful and protective immune response? This is where discovery becomes translational reality, and dengue is the first proof of concept for our platform across infectious diseases.” The company’s approach combines AI-native target identification with in-house wet-lab validation, creating a seamless in silico-to-in vivo pipeline. This integrated model aligns with regulatory trends favoring predictive, human-relevant methods that reduce reliance on animal testing. By leveraging the same platform across multiple pathogens, ImmunoPrecise is positioning its LENSai/HYFT technology as a versatile engine for future vaccine and therapeutic development in infectious diseases and immuno-oncology. The progress underscores the company’s end-to-end capabilities in biologics discovery and development. ImmunoPrecise continues to advance its mission of accelerating the creation of next-generation therapeutics through the integration of artificial intelligence and experimental biology. Forward-looking statements in this release include expectations around the vaccine candidate’s ability to elicit protective immune responses, the scalability of the platform to other diseases, and the timeline for future development stages. These statements are subject to risks and uncertainties, including the inherent challenges of preclinical research, manufacturing complexities, regulatory requirements, and competitive dynamics in biologics and vaccine development. Actual results may differ materially due to factors beyond the company’s control. Investors and stakeholders are encouraged to review the full risk disclosures in the company’s Annual Report on Form 20-F for the fiscal year ended April 30, 2025, available on SEDAR+ and EDGAR.